Wednesday, 28 September 2016

Hiprex


Hiprex is a brand name of methenamine, approved by the FDA in the following formulation(s):


HIPREX (methenamine hippurate - tablet; oral)



  • Manufacturer: SANOFI AVENTIS US

    Approved Prior to Jan 1, 1982

    Strength(s): 1GM [RLD][AB]

Has a generic version of Hiprex been approved?


Yes. The following products are equivalent to Hiprex:


methenamine hippurate tablet; oral



  • Manufacturer: COREPHARMA

    Approval date: June 20, 2003

    Strength(s): 1GM [AB]

UREX (methenamine hippurate tablet; oral)



  • Manufacturer: CNTY LINE PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 1GM [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Hiprex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Hiprex.

See also...

  • Hiprex Consumer Information (Wolters Kluwer)
  • Hiprex Consumer Information (Cerner Multum)
  • Hiprex Advanced Consumer Information (Micromedex)
  • Methenamine Consumer Information (Wolters Kluwer)
  • Methenamine Consumer Information (Cerner Multum)
  • Urasal Advanced Consumer Information (Micromedex)
  • Methenamine Advanced Consumer Information (Micromedex)
  • Methenamine AHFS DI Monographs (ASHP)
  • Methenamine Hippurate AHFS DI Monographs (ASHP)
  • Methenamine Mandelate AHFS DI Monographs (ASHP)

Idamycin PFS


Idamycin PFS is a brand name of idarubicin, approved by the FDA in the following formulation(s):


IDAMYCIN PFS (idarubicin hydrochloride - injectable; injection)



  • Manufacturer: PHARMACIA AND UPJOHN

    Approval date: February 17, 1997

    Strength(s): 1MG/ML [RLD][AP]

Has a generic version of Idamycin PFS been approved?


Yes. The following products are equivalent to Idamycin PFS:


idarubicin hydrochloride injectable; injection



  • Manufacturer: APP PHARMS

    Approval date: August 4, 2009

    Strength(s): 1MG/ML [AP]


  • Manufacturer: BEDFORD LABS

    Approval date: December 14, 2006

    Strength(s): 1MG/ML [AP]


  • Manufacturer: BEDFORD LABS

    Approval date: May 15, 2007

    Strength(s): 1MG/ML [AP]


  • Manufacturer: SANDOZ

    Approval date: March 29, 2011

    Strength(s): 1MG/ML [AP]

IDARUBICIN HYDROCHLORIDE PFS (idarubicin hydrochloride injectable; injection)



  • Manufacturer: TEVA PARENTERAL

    Approval date: May 1, 2002

    Strength(s): 1MG/ML [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Idamycin PFS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Idamycin PFS.

See also...

  • Idamycin PFS Consumer Information (Wolters Kluwer)
  • Idamycin PFS Consumer Information (Cerner Multum)
  • Idamycin PFS Advanced Consumer Information (Micromedex)
  • Idamycin PFS AHFS DI Monographs (ASHP)
  • Idarubicin Consumer Information (Wolters Kluwer)
  • Idarubicin Consumer Information (Cerner Multum)
  • Idarubicin Intravenous Advanced Consumer Information (Micromedex)
  • Idarubicin Hydrochloride AHFS DI Monographs (ASHP)

Axiron


Axiron is a brand name of testosterone, approved by the FDA in the following formulation(s):


AXIRON (testosterone - solution, metered; transdermal)



  • Manufacturer: ELI LILLY AND CO

    Approval date: November 23, 2010

    Strength(s): 30MG/1.5ML ACTIVATION [RLD]

Has a generic version of Axiron been approved?


No. There is currently no therapeutically equivalent version of Axiron available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Axiron. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Dermal penetration enhancers and drug delivery systems involving same
    Patent 6,299,900
    Issued: October 9, 2001
    Inventor(s): Reed; Barry Leonard & Morgan; Timothy Matthias & Finnin; Barrie Charles
    Assignee(s): Monash University
    A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
    Patent expiration dates:

    • February 19, 2017
      ✓ 
      Patent use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
      ✓ 
      Drug product




  • Dermal penetration enhancers and drug delivery systems involving same
    Patent 6,818,226
    Issued: November 16, 2004
    Inventor(s): Barry Leonard; Reed & Timothy Matthias; Morgan & Barrie Charles; Finnin
    Assignee(s): ACRUX DDS Pty. Ltd.
    A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
    Patent expiration dates:

    • February 19, 2017
      ✓ 
      Patent use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
      ✓ 
      Drug product




  • Transdermal delivery of hormones
    Patent 6,923,983
    Issued: August 2, 2005
    Inventor(s): Morgan; Timothy Matthias & Bakalova; Margarita Vladislavova & Klose; Karthryn Traci-Jane & Finnin; Barrie Charles & Reed; Barry Leonard
    Assignee(s): Acrux DDS PTY LTD
    The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone to an animal which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention
    Patent expiration dates:

    • February 19, 2017
      ✓ 
      Patent use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
      ✓ 
      Drug product




  • Dermal penetration enhancers and drug delivery systems involving the same
    Patent 8,071,075
    Issued: December 6, 2011
    Inventor(s): Reed; Barry Leonard & Morgan; Timothy Matthias & Finnin; Barrie Charles
    Assignee(s): Acrux DDS Pty Ltd.
    The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug thereof and at least one penetration enhancer selected from safe ester sunscreens.
    Patent expiration dates:

    • February 19, 2017
      ✓ 
      Patent use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • November 23, 2013 - NEW PRODUCT

See also...

  • Axiron Consumer Information (Drugs.com)
  • Axiron Solution Consumer Information (Wolters Kluwer)
  • Axiron Consumer Information (Cerner Multum)
  • Axiron Advanced Consumer Information (Micromedex)
  • Testosterone Consumer Information (Drugs.com)
  • Testosterone Consumer Information (Wolters Kluwer)
  • Testosterone Gel Consumer Information (Wolters Kluwer)
  • Testosterone Patch Consumer Information (Wolters Kluwer)
  • Testosterone Solution Consumer Information (Wolters Kluwer)
  • Testosterone buccal system Consumer Information (Cerner Multum)
  • Testosterone injection Consumer Information (Cerner Multum)
  • Testosterone topical Consumer Information (Cerner Multum)
  • Androplex Advanced Consumer Information (Micromedex)
  • Testosterone Buccal Advanced Consumer Information (Micromedex)
  • Testosterone Topical application Advanced Consumer Information (Micromedex)
  • Testosterone Transdermal Advanced Consumer Information (Micromedex)
  • Testosterone AHFS DI Monographs (ASHP)

Lido-Hyal




Lido-Hyal may be available in the countries listed below.


Ingredient matches for Lido-Hyal



Hyaluronidase

Hyaluronidase is reported as an ingredient of Lido-Hyal in the following countries:


  • Italy

Lidocaine

Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Lido-Hyal in the following countries:


  • Italy

International Drug Name Search

Sedazine




In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Sedazine



Xylazine

Xylazine hydrochloride (a derivative of Xylazine) is reported as an ingredient of Sedazine in the following countries:


  • Netherlands

  • United States

International Drug Name Search

Saljet Rinse flush


Generic Name: sodium chloride (flush) (SOE dee um KLOR ide)

Brand Names: Saljet Rinse, Saljet Sterile


What is Saljet Rinse (sodium chloride (flush))?

Sodium chloride is the chemical name for salt. Sodium chloride can reduce some types of bacteria.


Sodium chloride flush is used to clean out an intravenous (IV) catheter, which helps prevent blockage and removes any medicine left in the catheter area after you have received an IV infusion.


Sodium chloride may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Saljet Rinse (sodium chloride (flush))?


Call your doctor or tell your caregivers if your catheter, needle, or IV tubing becomes blocked or if the flush or IV medicine is not flowing normally. Stop using sodium chloride flush and call your doctor at once if you have severe irritation, swelling, warmth, redness, oozing, or pain around your catheter while using the flush.

What should I discuss with my health care provider before using Saljet Rinse (sodium chloride (flush))?


Before using sodium chloride flush, tell your doctor if you are allergic to any drugs.


How should I use Saljet Rinse (sodium chloride (flush))?


Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or more often than recommended.


You will use sodium chloride flush each time you use your IV catheter. Follow your doctor's instructions about how many times per day to use the flush.


Before using the flush, check the solution container to make sure there are no leaks in it. Do not use the medication if it has changed colors or has particles in it. Call your doctor for a new prescription.


Call your doctor or tell your caregivers if your catheter, needle, or IV tubing becomes blocked or if the flush or IV medicine is not flowing normally.

Throw away used needles in a puncture-proof container (ask your pharmacist where you can get one and how to dispose of it). Keep this container out of the reach of children and pets.


Store sodium chloride at room temperature away from moisture and heat. Keep all of your catheter flush supplies in a clean dry place when not in use.

What happens if I miss a dose?


If you use flush your catheter each time you use it, you are not likely to miss a dose.


What happens if I overdose?


An overdose of sodium chloride flush is unlikely to occur.


What should I avoid while using Saljet Rinse (sodium chloride (flush))?


Follow your doctor's instructions about any restrictions on food, beverages, or activity.


Saljet Rinse (sodium chloride (flush)) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using sodium chloride flush and call your doctor at once if you have any of these side effects while using the flush:

  • severe irritation;




  • swelling;




  • warmth;




  • redness;




  • oozing; or




  • pain.



Less serious side effects may include mild irritation around the catheter.


This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Saljet Rinse (sodium chloride (flush))?


It is not likely that other drugs you take orally or inject will have an effect on sodium chloride used to flush your catheter. But many drugs can interact with each other. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Saljet Rinse resources


  • Saljet Rinse Support Group
  • 0 Reviews · Be the first to review/rate this drug


Where can I get more information?


  • Your doctor or pharmacist can provide more information about sodium chloride flush.


Amiodaronã




Amiodaronã may be available in the countries listed below.


Ingredient matches for Amiodaronã



Amiodarone

Amiodarone hydrochloride (a derivative of Amiodarone) is reported as an ingredient of Amiodaronã in the following countries:


  • Romania

International Drug Name Search